Management of cutaneous adverse events caused by antineoplastic therapies: a single-center experience
Introduction Cutaneous adverse events can occur in patients treated with antineoplastic treatments, albeit their incidence has not been defined yet. The clinical presentation of CAEs related to anticancer treatments can vary. The purpose of our study is to characterize skin toxicities during oncological treatments, manage such adverse events to improve patients’ quality of life, and ensure therapeutic adherence. Methods We conducted a single-center prospective study which provided the enrollment of all patients referred to the Skin Toxicity Outpatient Clinic for the occurrence of cutaneous adverse events secondary to an ongoing antineoplastic treatment, between July 2021 and June 2023. We analyzed clinical features, and we described our therapeutic approach. Results Based on the type of drug assumed, chemotherapy-induced skin toxicity in 24 (38.7%) of the 62 evaluated patients, target therapies in 18 (29.0%), CDK4/6 cyclin inhibitors in 12 (19.4%), and immunotherapy in 6 (9.7%), while skin adverse events secondary to hormone therapy were seen in two patients. The most common cutaneous adverse event in our experience was rosaceiform rash of the face, followed by eczematous rash, hand-foot syndrome, and folliculitis. Conclusion The present study is aimed at describing the variability and heterogeneity of clinical manifestations of different pharmacological classes used in oncological patients, as well as the different pathogenesis of skin damage. Chemotherapy very frequently causes skin toxicities that are often underestimated by clinicians. Their adequate recognition and optimal treatment lead to total recovery and allow better adhesion to chemotherapy..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Supportive care in cancer - 32(2024), 3 vom: 29. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Starace, Michela [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Antineoplastic therapies |
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s00520-024-08407-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR054959632 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR054959632 | ||
| 003 | DE-627 | ||
| 005 | 20240320064706.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00520-024-08407-4 |2 doi | |
| 035 | |a (DE-627)SPR054959632 | ||
| 035 | |a (SPR)s00520-024-08407-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.81 |2 bkl | ||
| 100 | 1 | |a Starace, Michela |e verfasserin |0 (orcid)0000-0002-3981-1527 |4 aut | |
| 245 | 1 | 0 | |a Management of cutaneous adverse events caused by antineoplastic therapies: a single-center experience |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Introduction Cutaneous adverse events can occur in patients treated with antineoplastic treatments, albeit their incidence has not been defined yet. The clinical presentation of CAEs related to anticancer treatments can vary. The purpose of our study is to characterize skin toxicities during oncological treatments, manage such adverse events to improve patients’ quality of life, and ensure therapeutic adherence. Methods We conducted a single-center prospective study which provided the enrollment of all patients referred to the Skin Toxicity Outpatient Clinic for the occurrence of cutaneous adverse events secondary to an ongoing antineoplastic treatment, between July 2021 and June 2023. We analyzed clinical features, and we described our therapeutic approach. Results Based on the type of drug assumed, chemotherapy-induced skin toxicity in 24 (38.7%) of the 62 evaluated patients, target therapies in 18 (29.0%), CDK4/6 cyclin inhibitors in 12 (19.4%), and immunotherapy in 6 (9.7%), while skin adverse events secondary to hormone therapy were seen in two patients. The most common cutaneous adverse event in our experience was rosaceiform rash of the face, followed by eczematous rash, hand-foot syndrome, and folliculitis. Conclusion The present study is aimed at describing the variability and heterogeneity of clinical manifestations of different pharmacological classes used in oncological patients, as well as the different pathogenesis of skin damage. Chemotherapy very frequently causes skin toxicities that are often underestimated by clinicians. Their adequate recognition and optimal treatment lead to total recovery and allow better adhesion to chemotherapy. | ||
| 650 | 4 | |a Cutaneous adverse events |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Antineoplastic therapies |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Rash |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Chemotherapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a CDK 4/6 inhibitors |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Target therapy |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Immune checkpoint inhibitors |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Hand-foot syndrome |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Rosaceiform dermatitis |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Rapparini, Luca |0 (orcid)0000-0002-4029-941X |4 aut | |
| 700 | 1 | |a Cedirian, Stephano |0 (orcid)0000-0002-9783-7864 |4 aut | |
| 700 | 1 | |a Evangelista, Valeria |0 (orcid)0000-0002-1412-2776 |4 aut | |
| 700 | 1 | |a Pampaloni, Francesca |0 (orcid)0000-0003-2931-767X |4 aut | |
| 700 | 1 | |a Bruni, Francesca |0 (orcid)0000-0001-7248-425X |4 aut | |
| 700 | 1 | |a Misciali, Cosimo |0 (orcid)0000-0002-9765-0290 |4 aut | |
| 700 | 1 | |a Rubino, Daniela |4 aut | |
| 700 | 1 | |a Zamagni, Claudio |4 aut | |
| 700 | 1 | |a Pileri, Alessandro |0 (orcid)0000-0002-1025-7171 |4 aut | |
| 700 | 1 | |a Piraccini, Bianca Maria |0 (orcid)0000-0001-6537-9689 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Supportive care in cancer |d Springer Berlin Heidelberg, 1993 |g 32(2024), 3 vom: 29. Feb. |w (DE-627)SPR006567584 |w (DE-600)1463166-0 |x 1433-7339 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2024 |g number:3 |g day:29 |g month:02 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00520-024-08407-4 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.81 |q VZ |
| 951 | |a AR | ||
| 952 | |d 32 |j 2024 |e 3 |b 29 |c 02 | ||